nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—hematologic cancer	0.12	1	CbGaD
Levomilnacipran—ABCB1—Lenalidomide—hematologic cancer	0.0226	0.0391	CbGbCtD
Levomilnacipran—CYP2C8—Bortezomib—hematologic cancer	0.0204	0.0354	CbGbCtD
Levomilnacipran—CYP2D6—Lomustine—hematologic cancer	0.0198	0.0343	CbGbCtD
Levomilnacipran—CYP2D6—Idarubicin—hematologic cancer	0.0176	0.0305	CbGbCtD
Levomilnacipran—CYP2C19—Bortezomib—hematologic cancer	0.0171	0.0297	CbGbCtD
Levomilnacipran—CYP2C8—Ifosfamide—hematologic cancer	0.0157	0.0272	CbGbCtD
Levomilnacipran—CYP2D6—Hydroxyurea—hematologic cancer	0.015	0.026	CbGbCtD
Levomilnacipran—CYP2C19—Thalidomide—hematologic cancer	0.0149	0.0259	CbGbCtD
Levomilnacipran—CYP2C19—Teniposide—hematologic cancer	0.0142	0.0247	CbGbCtD
Levomilnacipran—CYP2C8—Nilotinib—hematologic cancer	0.0136	0.0236	CbGbCtD
Levomilnacipran—CYP3A4—Bexarotene—hematologic cancer	0.0135	0.0234	CbGbCtD
Levomilnacipran—ABCB1—Daunorubicin—hematologic cancer	0.0132	0.0229	CbGbCtD
Levomilnacipran—CYP2C19—Ifosfamide—hematologic cancer	0.0131	0.0228	CbGbCtD
Levomilnacipran—CYP2D6—Bortezomib—hematologic cancer	0.013	0.0226	CbGbCtD
Levomilnacipran—ABCB1—Alitretinoin—hematologic cancer	0.013	0.0225	CbGbCtD
Levomilnacipran—CYP3A4—Busulfan—hematologic cancer	0.0126	0.0218	CbGbCtD
Levomilnacipran—CYP3A4—Lomustine—hematologic cancer	0.0126	0.0218	CbGbCtD
Levomilnacipran—CYP2C19—Imatinib—hematologic cancer	0.0126	0.0218	CbGbCtD
Levomilnacipran—CYP3A4—Thiotepa—hematologic cancer	0.0112	0.0194	CbGbCtD
Levomilnacipran—ABCB1—Imatinib—hematologic cancer	0.0101	0.0176	CbGbCtD
Levomilnacipran—CYP2D6—Imatinib—hematologic cancer	0.00954	0.0166	CbGbCtD
Levomilnacipran—ABCB1—Nilotinib—hematologic cancer	0.0092	0.016	CbGbCtD
Levomilnacipran—ABCB1—Vinorelbine—hematologic cancer	0.00913	0.0158	CbGbCtD
Levomilnacipran—CYP3A4—Methoxsalen—hematologic cancer	0.00871	0.0151	CbGbCtD
Levomilnacipran—CYP2D6—Nilotinib—hematologic cancer	0.00867	0.015	CbGbCtD
Levomilnacipran—CYP2D6—Vinorelbine—hematologic cancer	0.0086	0.0149	CbGbCtD
Levomilnacipran—CYP3A4—Bortezomib—hematologic cancer	0.00828	0.0144	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—hematologic cancer	0.00827	0.0143	CbGbCtD
Levomilnacipran—ABCB1—Dasatinib—hematologic cancer	0.00813	0.0141	CbGbCtD
Levomilnacipran—ABCB1—Mitoxantrone—hematologic cancer	0.00803	0.0139	CbGbCtD
Levomilnacipran—CYP3A4—Daunorubicin—hematologic cancer	0.00792	0.0137	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—hematologic cancer	0.00748	0.013	CbGbCtD
Levomilnacipran—ABCB1—Betamethasone—hematologic cancer	0.00716	0.0124	CbGbCtD
Levomilnacipran—ABCB1—Gemcitabine—hematologic cancer	0.0071	0.0123	CbGbCtD
Levomilnacipran—ABCB1—Prednisolone—hematologic cancer	0.00707	0.0123	CbGbCtD
Levomilnacipran—CYP3A4—Cytarabine—hematologic cancer	0.00699	0.0121	CbGbCtD
Levomilnacipran—CYP3A4—Teniposide—hematologic cancer	0.00688	0.0119	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—hematologic cancer	0.00667	0.0116	CbGbCtD
Levomilnacipran—CYP3A4—Ifosfamide—hematologic cancer	0.00635	0.011	CbGbCtD
Levomilnacipran—ABCB1—Irinotecan—hematologic cancer	0.00633	0.011	CbGbCtD
Levomilnacipran—CYP2C8—Dexamethasone—hematologic cancer	0.00615	0.0107	CbGbCtD
Levomilnacipran—CYP3A4—Imatinib—hematologic cancer	0.00607	0.0105	CbGbCtD
Levomilnacipran—CYP3A4—Ruxolitinib—hematologic cancer	0.00571	0.00991	CbGbCtD
Levomilnacipran—ABCB1—Vinblastine—hematologic cancer	0.00562	0.00976	CbGbCtD
Levomilnacipran—ABCB1—Vincristine—hematologic cancer	0.00553	0.00959	CbGbCtD
Levomilnacipran—CYP3A4—Nilotinib—hematologic cancer	0.00551	0.00957	CbGbCtD
Levomilnacipran—CYP3A4—Vinorelbine—hematologic cancer	0.00547	0.00948	CbGbCtD
Levomilnacipran—CYP2D6—Vinblastine—hematologic cancer	0.0053	0.00919	CbGbCtD
Levomilnacipran—CYP2C19—Dexamethasone—hematologic cancer	0.00516	0.00896	CbGbCtD
Levomilnacipran—ABCB1—Cisplatin—hematologic cancer	0.00516	0.00895	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—hematologic cancer	0.00507	0.00879	CbGbCtD
Levomilnacipran—CYP3A4—Triamcinolone—hematologic cancer	0.005	0.00868	CbGbCtD
Levomilnacipran—CYP3A4—Dasatinib—hematologic cancer	0.00487	0.00845	CbGbCtD
Levomilnacipran—CYP3A4—Mitoxantrone—hematologic cancer	0.00481	0.00835	CbGbCtD
Levomilnacipran—CYP3A4—Betamethasone—hematologic cancer	0.00429	0.00744	CbGbCtD
Levomilnacipran—CYP3A4—Prednisolone—hematologic cancer	0.00423	0.00734	CbGbCtD
Levomilnacipran—ABCB1—Dexamethasone—hematologic cancer	0.00417	0.00723	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—hematologic cancer	0.004	0.00694	CbGbCtD
Levomilnacipran—CYP2D6—Dexamethasone—hematologic cancer	0.00392	0.00681	CbGbCtD
Levomilnacipran—CYP3A4—Irinotecan—hematologic cancer	0.00379	0.00657	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—hematologic cancer	0.00346	0.00599	CbGbCtD
Levomilnacipran—CYP3A4—Vinblastine—hematologic cancer	0.00337	0.00585	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—hematologic cancer	0.00335	0.00581	CbGbCtD
Levomilnacipran—CYP3A4—Vincristine—hematologic cancer	0.00331	0.00575	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—hematologic cancer	0.00326	0.00565	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—hematologic cancer	0.00304	0.00527	CbGbCtD
Levomilnacipran—CYP3A4—Dexamethasone—hematologic cancer	0.0025	0.00433	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—hematologic cancer	0.00207	0.00359	CbGbCtD
Levomilnacipran—CYP2J2—lung—hematologic cancer	0.000512	0.0842	CbGeAlD
Levomilnacipran—CYP2J2—testis—hematologic cancer	0.000483	0.0794	CbGeAlD
Levomilnacipran—SLC6A4—hematopoietic system—hematologic cancer	0.000476	0.0782	CbGeAlD
Levomilnacipran—CYP2C19—hematopoietic system—hematologic cancer	0.000394	0.0648	CbGeAlD
Levomilnacipran—CYP2C8—hematopoietic system—hematologic cancer	0.000344	0.0565	CbGeAlD
Levomilnacipran—SLC6A2—gonad—hematologic cancer	0.000318	0.0523	CbGeAlD
Levomilnacipran—SLC6A4—blood—hematologic cancer	0.000315	0.0518	CbGeAlD
Levomilnacipran—SLC6A4—lung—hematologic cancer	0.000276	0.0454	CbGeAlD
Levomilnacipran—CYP2C19—blood—hematologic cancer	0.000261	0.0429	CbGeAlD
Levomilnacipran—SLC6A2—lung—hematologic cancer	0.000243	0.04	CbGeAlD
Levomilnacipran—CYP3A4—hematopoietic system—hematologic cancer	0.000233	0.0383	CbGeAlD
Levomilnacipran—SLC6A2—testis—hematologic cancer	0.000229	0.0377	CbGeAlD
Levomilnacipran—CYP2D6—hematopoietic system—hematologic cancer	0.000229	0.0377	CbGeAlD
Levomilnacipran—CYP2C8—blood—hematologic cancer	0.000228	0.0374	CbGeAlD
Levomilnacipran—CYP2C8—testis—hematologic cancer	0.000189	0.031	CbGeAlD
Levomilnacipran—SLC6A2—lymph node—hematologic cancer	0.000166	0.0273	CbGeAlD
Levomilnacipran—ABCB1—hematopoietic system—hematologic cancer	0.000165	0.0271	CbGeAlD
Levomilnacipran—CYP3A4—blood—hematologic cancer	0.000154	0.0254	CbGeAlD
Levomilnacipran—CYP2D6—blood—hematologic cancer	0.000152	0.025	CbGeAlD
Levomilnacipran—CYP2D6—testis—hematologic cancer	0.000126	0.0206	CbGeAlD
Levomilnacipran—ABCB1—gonad—hematologic cancer	0.000125	0.0206	CbGeAlD
Levomilnacipran—ABCB1—blood—hematologic cancer	0.000109	0.018	CbGeAlD
Levomilnacipran—ABCB1—bone marrow—hematologic cancer	0.000106	0.0174	CbGeAlD
Levomilnacipran—ABCB1—lung—hematologic cancer	9.58e-05	0.0157	CbGeAlD
Levomilnacipran—ABCB1—testis—hematologic cancer	9.04e-05	0.0149	CbGeAlD
Levomilnacipran—ABCB1—lymph node—hematologic cancer	6.55e-05	0.0108	CbGeAlD
Levomilnacipran—Eye disorder—Epirubicin—hematologic cancer	3.77e-05	0.000151	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—hematologic cancer	3.77e-05	0.000151	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—hematologic cancer	3.76e-05	0.000151	CcSEcCtD
Levomilnacipran—Headache—Gemcitabine—hematologic cancer	3.75e-05	0.000151	CcSEcCtD
Levomilnacipran—Nausea—Vincristine—hematologic cancer	3.75e-05	0.000151	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—hematologic cancer	3.75e-05	0.00015	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—hematologic cancer	3.75e-05	0.00015	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—hematologic cancer	3.74e-05	0.00015	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisolone—hematologic cancer	3.72e-05	0.000149	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—hematologic cancer	3.72e-05	0.000149	CcSEcCtD
Levomilnacipran—Dyspepsia—Betamethasone—hematologic cancer	3.71e-05	0.000149	CcSEcCtD
Levomilnacipran—Dyspepsia—Dexamethasone—hematologic cancer	3.71e-05	0.000149	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—hematologic cancer	3.69e-05	0.000148	CcSEcCtD
Levomilnacipran—Urticaria—Triamcinolone—hematologic cancer	3.69e-05	0.000148	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—hematologic cancer	3.68e-05	0.000148	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—hematologic cancer	3.68e-05	0.000148	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—hematologic cancer	3.67e-05	0.000147	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—hematologic cancer	3.67e-05	0.000147	CcSEcCtD
Levomilnacipran—Body temperature increased—Triamcinolone—hematologic cancer	3.67e-05	0.000147	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—hematologic cancer	3.66e-05	0.000147	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—hematologic cancer	3.66e-05	0.000147	CcSEcCtD
Levomilnacipran—Decreased appetite—Betamethasone—hematologic cancer	3.66e-05	0.000147	CcSEcCtD
Levomilnacipran—Decreased appetite—Dexamethasone—hematologic cancer	3.66e-05	0.000147	CcSEcCtD
Levomilnacipran—Nausea—Mitoxantrone—hematologic cancer	3.65e-05	0.000147	CcSEcCtD
Levomilnacipran—Nausea—Irinotecan—hematologic cancer	3.65e-05	0.000147	CcSEcCtD
Levomilnacipran—Infection—Prednisone—hematologic cancer	3.64e-05	0.000146	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—hematologic cancer	3.64e-05	0.000146	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.64e-05	0.000146	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.64e-05	0.000146	CcSEcCtD
Levomilnacipran—Fatigue—Dexamethasone—hematologic cancer	3.63e-05	0.000146	CcSEcCtD
Levomilnacipran—Fatigue—Betamethasone—hematologic cancer	3.63e-05	0.000146	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—hematologic cancer	3.62e-05	0.000145	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—hematologic cancer	3.62e-05	0.000145	CcSEcCtD
Levomilnacipran—Shock—Prednisone—hematologic cancer	3.61e-05	0.000145	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—hematologic cancer	3.6e-05	0.000144	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—hematologic cancer	3.58e-05	0.000144	CcSEcCtD
Levomilnacipran—Skin disorder—Prednisone—hematologic cancer	3.56e-05	0.000143	CcSEcCtD
Levomilnacipran—Nausea—Gemcitabine—hematologic cancer	3.56e-05	0.000143	CcSEcCtD
Levomilnacipran—Vomiting—Cisplatin—hematologic cancer	3.55e-05	0.000142	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisone—hematologic cancer	3.55e-05	0.000142	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—hematologic cancer	3.54e-05	0.000142	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—hematologic cancer	3.54e-05	0.000142	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—hematologic cancer	3.53e-05	0.000142	CcSEcCtD
Levomilnacipran—Rash—Cisplatin—hematologic cancer	3.52e-05	0.000141	CcSEcCtD
Levomilnacipran—Dermatitis—Cisplatin—hematologic cancer	3.52e-05	0.000141	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—hematologic cancer	3.52e-05	0.000141	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—hematologic cancer	3.5e-05	0.00014	CcSEcCtD
Levomilnacipran—Anorexia—Prednisone—hematologic cancer	3.5e-05	0.00014	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—hematologic cancer	3.49e-05	0.00014	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—hematologic cancer	3.47e-05	0.000139	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—hematologic cancer	3.47e-05	0.000139	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—hematologic cancer	3.46e-05	0.000139	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—hematologic cancer	3.45e-05	0.000138	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.44e-05	0.000138	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Betamethasone—hematologic cancer	3.44e-05	0.000138	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—hematologic cancer	3.44e-05	0.000138	CcSEcCtD
Levomilnacipran—Hypersensitivity—Triamcinolone—hematologic cancer	3.42e-05	0.000137	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—hematologic cancer	3.39e-05	0.000136	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—hematologic cancer	3.38e-05	0.000136	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—hematologic cancer	3.37e-05	0.000135	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—hematologic cancer	3.36e-05	0.000135	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—hematologic cancer	3.35e-05	0.000134	CcSEcCtD
Levomilnacipran—Urticaria—Dexamethasone—hematologic cancer	3.35e-05	0.000134	CcSEcCtD
Levomilnacipran—Urticaria—Betamethasone—hematologic cancer	3.35e-05	0.000134	CcSEcCtD
Levomilnacipran—Dizziness—Prednisolone—hematologic cancer	3.34e-05	0.000134	CcSEcCtD
Levomilnacipran—Asthenia—Triamcinolone—hematologic cancer	3.33e-05	0.000134	CcSEcCtD
Levomilnacipran—Body temperature increased—Dexamethasone—hematologic cancer	3.33e-05	0.000134	CcSEcCtD
Levomilnacipran—Abdominal pain—Dexamethasone—hematologic cancer	3.33e-05	0.000134	CcSEcCtD
Levomilnacipran—Body temperature increased—Betamethasone—hematologic cancer	3.33e-05	0.000134	CcSEcCtD
Levomilnacipran—Abdominal pain—Betamethasone—hematologic cancer	3.33e-05	0.000134	CcSEcCtD
Levomilnacipran—Nausea—Cisplatin—hematologic cancer	3.32e-05	0.000133	CcSEcCtD
Levomilnacipran—Insomnia—Prednisone—hematologic cancer	3.32e-05	0.000133	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—hematologic cancer	3.31e-05	0.000133	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisone—hematologic cancer	3.29e-05	0.000132	CcSEcCtD
Levomilnacipran—Pruritus—Triamcinolone—hematologic cancer	3.28e-05	0.000132	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—hematologic cancer	3.27e-05	0.000131	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—hematologic cancer	3.25e-05	0.000131	CcSEcCtD
Levomilnacipran—Vomiting—Etoposide—hematologic cancer	3.25e-05	0.000131	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—hematologic cancer	3.25e-05	0.00013	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—hematologic cancer	3.23e-05	0.00013	CcSEcCtD
Levomilnacipran—Dyspepsia—Prednisone—hematologic cancer	3.23e-05	0.00013	CcSEcCtD
Levomilnacipran—Rash—Etoposide—hematologic cancer	3.23e-05	0.000129	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—hematologic cancer	3.22e-05	0.000129	CcSEcCtD
Levomilnacipran—Headache—Etoposide—hematologic cancer	3.21e-05	0.000129	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—hematologic cancer	3.2e-05	0.000129	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—hematologic cancer	3.2e-05	0.000128	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—hematologic cancer	3.19e-05	0.000128	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—hematologic cancer	3.19e-05	0.000128	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—hematologic cancer	3.19e-05	0.000128	CcSEcCtD
Levomilnacipran—Rash—Prednisolone—hematologic cancer	3.18e-05	0.000128	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisolone—hematologic cancer	3.18e-05	0.000128	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.18e-05	0.000127	CcSEcCtD
Levomilnacipran—Fatigue—Prednisone—hematologic cancer	3.16e-05	0.000127	CcSEcCtD
Levomilnacipran—Headache—Prednisolone—hematologic cancer	3.16e-05	0.000127	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—hematologic cancer	3.15e-05	0.000126	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—hematologic cancer	3.15e-05	0.000126	CcSEcCtD
Levomilnacipran—Constipation—Prednisone—hematologic cancer	3.14e-05	0.000126	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—hematologic cancer	3.11e-05	0.000125	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—hematologic cancer	3.09e-05	0.000124	CcSEcCtD
Levomilnacipran—Dizziness—Triamcinolone—hematologic cancer	3.07e-05	0.000123	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—hematologic cancer	3.07e-05	0.000123	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—hematologic cancer	3.05e-05	0.000122	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—hematologic cancer	3.05e-05	0.000122	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—hematologic cancer	3.04e-05	0.000122	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—hematologic cancer	3.03e-05	0.000122	CcSEcCtD
Levomilnacipran—Asthenia—Betamethasone—hematologic cancer	3.02e-05	0.000121	CcSEcCtD
Levomilnacipran—Asthenia—Dexamethasone—hematologic cancer	3.02e-05	0.000121	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—hematologic cancer	3.01e-05	0.000121	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—hematologic cancer	3e-05	0.00012	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Prednisone—hematologic cancer	3e-05	0.00012	CcSEcCtD
Levomilnacipran—Nausea—Prednisolone—hematologic cancer	3e-05	0.00012	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—hematologic cancer	2.99e-05	0.00012	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—hematologic cancer	2.99e-05	0.00012	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—hematologic cancer	2.98e-05	0.00012	CcSEcCtD
Levomilnacipran—Pruritus—Betamethasone—hematologic cancer	2.98e-05	0.00012	CcSEcCtD
Levomilnacipran—Pruritus—Dexamethasone—hematologic cancer	2.98e-05	0.00012	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—hematologic cancer	2.98e-05	0.000119	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.97e-05	0.000119	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—hematologic cancer	2.96e-05	0.000119	CcSEcCtD
Levomilnacipran—Vomiting—Triamcinolone—hematologic cancer	2.95e-05	0.000118	CcSEcCtD
Levomilnacipran—Rash—Triamcinolone—hematologic cancer	2.93e-05	0.000117	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—hematologic cancer	2.93e-05	0.000117	CcSEcCtD
Levomilnacipran—Dermatitis—Triamcinolone—hematologic cancer	2.92e-05	0.000117	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—hematologic cancer	2.92e-05	0.000117	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—hematologic cancer	2.92e-05	0.000117	CcSEcCtD
Levomilnacipran—Urticaria—Prednisone—hematologic cancer	2.91e-05	0.000117	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—hematologic cancer	2.91e-05	0.000117	CcSEcCtD
Levomilnacipran—Headache—Triamcinolone—hematologic cancer	2.91e-05	0.000117	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—hematologic cancer	2.9e-05	0.000116	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—hematologic cancer	2.9e-05	0.000116	CcSEcCtD
Levomilnacipran—Diarrhoea—Dexamethasone—hematologic cancer	2.88e-05	0.000116	CcSEcCtD
Levomilnacipran—Diarrhoea—Betamethasone—hematologic cancer	2.88e-05	0.000116	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—hematologic cancer	2.87e-05	0.000115	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—hematologic cancer	2.86e-05	0.000115	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—hematologic cancer	2.86e-05	0.000115	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—hematologic cancer	2.85e-05	0.000114	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—hematologic cancer	2.82e-05	0.000113	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—hematologic cancer	2.82e-05	0.000113	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—hematologic cancer	2.81e-05	0.000113	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—hematologic cancer	2.81e-05	0.000113	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—hematologic cancer	2.81e-05	0.000113	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—hematologic cancer	2.8e-05	0.000112	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—hematologic cancer	2.79e-05	0.000112	CcSEcCtD
Levomilnacipran—Dizziness—Betamethasone—hematologic cancer	2.79e-05	0.000112	CcSEcCtD
Levomilnacipran—Dizziness—Dexamethasone—hematologic cancer	2.79e-05	0.000112	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—hematologic cancer	2.77e-05	0.000111	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—hematologic cancer	2.77e-05	0.000111	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—hematologic cancer	2.77e-05	0.000111	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—hematologic cancer	2.76e-05	0.000111	CcSEcCtD
Levomilnacipran—Nausea—Triamcinolone—hematologic cancer	2.76e-05	0.000111	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—hematologic cancer	2.75e-05	0.00011	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.75e-05	0.00011	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—hematologic cancer	2.73e-05	0.00011	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—hematologic cancer	2.73e-05	0.00011	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—hematologic cancer	2.73e-05	0.000109	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—hematologic cancer	2.71e-05	0.000109	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisone—hematologic cancer	2.7e-05	0.000108	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—hematologic cancer	2.7e-05	0.000108	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—hematologic cancer	2.68e-05	0.000108	CcSEcCtD
Levomilnacipran—Vomiting—Dexamethasone—hematologic cancer	2.68e-05	0.000107	CcSEcCtD
Levomilnacipran—Vomiting—Betamethasone—hematologic cancer	2.68e-05	0.000107	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—hematologic cancer	2.66e-05	0.000107	CcSEcCtD
Levomilnacipran—Rash—Dexamethasone—hematologic cancer	2.66e-05	0.000107	CcSEcCtD
Levomilnacipran—Rash—Betamethasone—hematologic cancer	2.66e-05	0.000107	CcSEcCtD
Levomilnacipran—Dermatitis—Betamethasone—hematologic cancer	2.65e-05	0.000106	CcSEcCtD
Levomilnacipran—Dermatitis—Dexamethasone—hematologic cancer	2.65e-05	0.000106	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.65e-05	0.000106	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—hematologic cancer	2.64e-05	0.000106	CcSEcCtD
Levomilnacipran—Headache—Dexamethasone—hematologic cancer	2.64e-05	0.000106	CcSEcCtD
Levomilnacipran—Headache—Betamethasone—hematologic cancer	2.64e-05	0.000106	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—hematologic cancer	2.64e-05	0.000106	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—hematologic cancer	2.63e-05	0.000106	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—hematologic cancer	2.61e-05	0.000105	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—hematologic cancer	2.6e-05	0.000104	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—hematologic cancer	2.6e-05	0.000104	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—hematologic cancer	2.6e-05	0.000104	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—hematologic cancer	2.59e-05	0.000104	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—hematologic cancer	2.59e-05	0.000104	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—hematologic cancer	2.58e-05	0.000103	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—hematologic cancer	2.58e-05	0.000103	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—hematologic cancer	2.57e-05	0.000103	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—hematologic cancer	2.56e-05	0.000103	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—hematologic cancer	2.55e-05	0.000102	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—hematologic cancer	2.53e-05	0.000102	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—hematologic cancer	2.53e-05	0.000101	CcSEcCtD
Levomilnacipran—Diarrhoea—Prednisone—hematologic cancer	2.51e-05	0.000101	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—hematologic cancer	2.51e-05	0.000101	CcSEcCtD
Levomilnacipran—Nausea—Betamethasone—hematologic cancer	2.5e-05	0.0001	CcSEcCtD
Levomilnacipran—Nausea—Dexamethasone—hematologic cancer	2.5e-05	0.0001	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—hematologic cancer	2.49e-05	0.0001	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—hematologic cancer	2.48e-05	9.95e-05	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.48e-05	9.94e-05	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—hematologic cancer	2.47e-05	9.92e-05	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—hematologic cancer	2.45e-05	9.84e-05	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—hematologic cancer	2.44e-05	9.77e-05	CcSEcCtD
Levomilnacipran—Dizziness—Prednisone—hematologic cancer	2.43e-05	9.73e-05	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—hematologic cancer	2.42e-05	9.72e-05	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—hematologic cancer	2.42e-05	9.72e-05	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—hematologic cancer	2.4e-05	9.63e-05	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—hematologic cancer	2.38e-05	9.56e-05	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—hematologic cancer	2.37e-05	9.49e-05	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—hematologic cancer	2.36e-05	9.47e-05	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—hematologic cancer	2.35e-05	9.41e-05	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—hematologic cancer	2.34e-05	9.37e-05	CcSEcCtD
Levomilnacipran—Vomiting—Prednisone—hematologic cancer	2.33e-05	9.36e-05	CcSEcCtD
Levomilnacipran—Rash—Prednisone—hematologic cancer	2.31e-05	9.28e-05	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisone—hematologic cancer	2.31e-05	9.27e-05	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—hematologic cancer	2.31e-05	9.26e-05	CcSEcCtD
Levomilnacipran—Headache—Prednisone—hematologic cancer	2.3e-05	9.22e-05	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.29e-05	9.19e-05	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—hematologic cancer	2.29e-05	9.18e-05	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—hematologic cancer	2.28e-05	9.14e-05	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—hematologic cancer	2.27e-05	9.11e-05	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—hematologic cancer	2.27e-05	9.1e-05	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—hematologic cancer	2.27e-05	9.1e-05	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—hematologic cancer	2.26e-05	9.06e-05	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—hematologic cancer	2.2e-05	8.82e-05	CcSEcCtD
Levomilnacipran—Nausea—Prednisone—hematologic cancer	2.18e-05	8.74e-05	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.17e-05	8.71e-05	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—hematologic cancer	2.17e-05	8.7e-05	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—hematologic cancer	2.11e-05	8.48e-05	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—hematologic cancer	2.11e-05	8.46e-05	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—hematologic cancer	2.1e-05	8.42e-05	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—hematologic cancer	2.1e-05	8.42e-05	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—hematologic cancer	2.1e-05	8.41e-05	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—hematologic cancer	2.06e-05	8.26e-05	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—hematologic cancer	2.03e-05	8.14e-05	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—hematologic cancer	2.03e-05	8.13e-05	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—hematologic cancer	1.96e-05	7.87e-05	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—hematologic cancer	1.96e-05	7.85e-05	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—hematologic cancer	1.95e-05	7.82e-05	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—hematologic cancer	1.93e-05	7.75e-05	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—hematologic cancer	1.93e-05	7.75e-05	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—hematologic cancer	1.92e-05	7.7e-05	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—hematologic cancer	1.9e-05	7.64e-05	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—hematologic cancer	1.9e-05	7.61e-05	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—hematologic cancer	1.88e-05	7.53e-05	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—hematologic cancer	1.82e-05	7.32e-05	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—hematologic cancer	1.82e-05	7.31e-05	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—hematologic cancer	1.82e-05	7.29e-05	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—hematologic cancer	1.81e-05	7.26e-05	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—hematologic cancer	1.81e-05	7.25e-05	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—hematologic cancer	1.8e-05	7.21e-05	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—hematologic cancer	1.76e-05	7.04e-05	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—hematologic cancer	1.7e-05	6.84e-05	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—hematologic cancer	1.69e-05	6.77e-05	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—hematologic cancer	1.67e-05	6.71e-05	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—hematologic cancer	1.67e-05	6.71e-05	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—hematologic cancer	1.66e-05	6.67e-05	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—hematologic cancer	1.58e-05	6.33e-05	CcSEcCtD
Levomilnacipran—CYP3A4—Metabolism—ASNS—hematologic cancer	9.64e-06	0.000201	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	9.59e-06	0.0002	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—IDH2—hematologic cancer	9.56e-06	0.000199	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMMR—hematologic cancer	9.56e-06	0.000199	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AGRN—hematologic cancer	9.5e-06	0.000198	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—IDH1—hematologic cancer	9.44e-06	0.000197	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCC3—hematologic cancer	9.33e-06	0.000194	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TXN—hematologic cancer	9.33e-06	0.000194	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTO1—hematologic cancer	9.33e-06	0.000194	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	9.24e-06	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ARNTL—hematologic cancer	9.21e-06	0.000192	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HDC—hematologic cancer	9.14e-06	0.00019	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SPHK1—hematologic cancer	9.13e-06	0.00019	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTEN—hematologic cancer	9.08e-06	0.000189	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	9.07e-06	0.000189	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—IDH2—hematologic cancer	9.01e-06	0.000188	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMMR—hematologic cancer	9.01e-06	0.000188	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ARNTL—hematologic cancer	8.99e-06	0.000187	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ACP5—hematologic cancer	8.96e-06	0.000187	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA9—hematologic cancer	8.96e-06	0.000187	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOR2—hematologic cancer	8.84e-06	0.000184	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	8.82e-06	0.000184	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	8.8e-06	0.000183	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—UGT1A1—hematologic cancer	8.77e-06	0.000183	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA9—hematologic cancer	8.74e-06	0.000182	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ACP5—hematologic cancer	8.74e-06	0.000182	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—EP300—hematologic cancer	8.66e-06	0.00018	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOR2—hematologic cancer	8.63e-06	0.00018	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CRABP1—hematologic cancer	8.53e-06	0.000178	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC22A1—hematologic cancer	8.53e-06	0.000178	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ARNTL—hematologic cancer	8.47e-06	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—IDH1—hematologic cancer	8.42e-06	0.000175	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CDA—hematologic cancer	8.36e-06	0.000174	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTO1—hematologic cancer	8.33e-06	0.000173	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCC3—hematologic cancer	8.33e-06	0.000173	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TXN—hematologic cancer	8.33e-06	0.000173	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALOX5—hematologic cancer	8.32e-06	0.000173	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA9—hematologic cancer	8.24e-06	0.000172	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ACP5—hematologic cancer	8.24e-06	0.000172	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—IDH1—hematologic cancer	8.22e-06	0.000171	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	8.22e-06	0.000171	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	8.15e-06	0.00017	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SPHK1—hematologic cancer	8.15e-06	0.00017	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOR2—hematologic cancer	8.13e-06	0.000169	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ABCC3—hematologic cancer	8.13e-06	0.000169	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TXN—hematologic cancer	8.13e-06	0.000169	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTO1—hematologic cancer	8.13e-06	0.000169	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NUP98—hematologic cancer	8.05e-06	0.000168	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PC—hematologic cancer	8.05e-06	0.000168	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SPHK1—hematologic cancer	7.96e-06	0.000166	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—UGT1A1—hematologic cancer	7.83e-06	0.000163	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ADCY7—hematologic cancer	7.82e-06	0.000163	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOA3—hematologic cancer	7.82e-06	0.000163	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC35B2—hematologic cancer	7.77e-06	0.000162	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GBA—hematologic cancer	7.77e-06	0.000162	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NUP214—hematologic cancer	7.76e-06	0.000162	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—IDH1—hematologic cancer	7.75e-06	0.000161	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.68e-06	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TXN—hematologic cancer	7.66e-06	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCC3—hematologic cancer	7.66e-06	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTO1—hematologic cancer	7.66e-06	0.00016	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—UGT1A1—hematologic cancer	7.64e-06	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC22A1—hematologic cancer	7.62e-06	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CRABP1—hematologic cancer	7.62e-06	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCG2—hematologic cancer	7.61e-06	0.000158	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTR—hematologic cancer	7.61e-06	0.000158	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SPHK1—hematologic cancer	7.5e-06	0.000156	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	7.49e-06	0.000156	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ENO2—hematologic cancer	7.46e-06	0.000155	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CRABP1—hematologic cancer	7.44e-06	0.000155	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC22A1—hematologic cancer	7.44e-06	0.000155	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALOX5—hematologic cancer	7.42e-06	0.000155	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALOX5—hematologic cancer	7.25e-06	0.000151	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	7.24e-06	0.000151	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTT1—hematologic cancer	7.24e-06	0.000151	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—UGT1A1—hematologic cancer	7.2e-06	0.00015	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NUP98—hematologic cancer	7.19e-06	0.00015	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.12e-06	0.000148	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTAP—hematologic cancer	7.11e-06	0.000148	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SDC1—hematologic cancer	7.07e-06	0.000147	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NUP98—hematologic cancer	7.02e-06	0.000146	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC22A1—hematologic cancer	7.01e-06	0.000146	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CRABP1—hematologic cancer	7.01e-06	0.000146	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ADCY7—hematologic cancer	6.98e-06	0.000145	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOA3—hematologic cancer	6.98e-06	0.000145	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NUP214—hematologic cancer	6.93e-06	0.000144	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.86e-06	0.000143	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALOX5—hematologic cancer	6.83e-06	0.000142	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ADCY7—hematologic cancer	6.81e-06	0.000142	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOA3—hematologic cancer	6.81e-06	0.000142	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTR—hematologic cancer	6.79e-06	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCG2—hematologic cancer	6.79e-06	0.000141	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NUP214—hematologic cancer	6.76e-06	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.76e-06	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.67e-06	0.000139	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ENO2—hematologic cancer	6.66e-06	0.000139	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ABCG2—hematologic cancer	6.63e-06	0.000138	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTR—hematologic cancer	6.63e-06	0.000138	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NUP98—hematologic cancer	6.61e-06	0.000138	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ENO2—hematologic cancer	6.5e-06	0.000135	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—hematologic cancer	6.46e-06	0.000135	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOA3—hematologic cancer	6.42e-06	0.000134	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ADCY7—hematologic cancer	6.42e-06	0.000134	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—hematologic cancer	6.4e-06	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.38e-06	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NUP214—hematologic cancer	6.37e-06	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.36e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FHL2—hematologic cancer	6.34e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SDC1—hematologic cancer	6.31e-06	0.000131	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—hematologic cancer	6.3e-06	0.000131	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTR—hematologic cancer	6.24e-06	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCG2—hematologic cancer	6.24e-06	0.00013	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AGRN—hematologic cancer	6.21e-06	0.000129	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SDC1—hematologic cancer	6.16e-06	0.000128	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ENO2—hematologic cancer	6.12e-06	0.000128	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	6.12e-06	0.000127	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.03e-06	0.000126	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NQO1—hematologic cancer	6.01e-06	0.000125	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CD44—hematologic cancer	6.01e-06	0.000125	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.95e-06	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—hematologic cancer	5.94e-06	0.000124	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.9e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMMR—hematologic cancer	5.89e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—IDH2—hematologic cancer	5.89e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.89e-06	0.000123	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SDC1—hematologic cancer	5.81e-06	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.69e-06	0.000119	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYCS—hematologic cancer	5.69e-06	0.000119	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	5.65e-06	0.000118	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ARNTL—hematologic cancer	5.54e-06	0.000115	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	5.52e-06	0.000115	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA9—hematologic cancer	5.39e-06	0.000112	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ACP5—hematologic cancer	5.39e-06	0.000112	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CD44—hematologic cancer	5.37e-06	0.000112	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NQO1—hematologic cancer	5.37e-06	0.000112	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOR2—hematologic cancer	5.32e-06	0.000111	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.26e-06	0.000109	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NQO1—hematologic cancer	5.24e-06	0.000109	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CD44—hematologic cancer	5.24e-06	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—hematologic cancer	5.23e-06	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.09e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYCS—hematologic cancer	5.08e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—IDH1—hematologic cancer	5.07e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	5.05e-06	0.000105	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—hematologic cancer	5.02e-06	0.000104	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTO1—hematologic cancer	5.01e-06	0.000104	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TXN—hematologic cancer	5.01e-06	0.000104	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCC3—hematologic cancer	5.01e-06	0.000104	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYCS—hematologic cancer	4.96e-06	0.000103	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CD44—hematologic cancer	4.94e-06	0.000103	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NQO1—hematologic cancer	4.94e-06	0.000103	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HSP90AA1—hematologic cancer	4.93e-06	0.000103	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.9e-06	0.000102	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.85e-06	0.000101	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCB1—hematologic cancer	4.75e-06	9.89e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.71e-06	9.81e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYCS—hematologic cancer	4.67e-06	9.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	4.64e-06	9.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOR1—hematologic cancer	4.61e-06	9.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—hematologic cancer	4.61e-06	9.6e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CRABP1—hematologic cancer	4.58e-06	9.54e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC22A1—hematologic cancer	4.58e-06	9.54e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.54e-06	9.46e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—hematologic cancer	4.48e-06	9.32e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.46e-06	9.3e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—hematologic cancer	4.37e-06	9.1e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.33e-06	9.02e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NUP98—hematologic cancer	4.32e-06	9.01e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCB1—hematologic cancer	4.24e-06	8.83e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.2e-06	8.74e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.2e-06	8.74e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NUP214—hematologic cancer	4.17e-06	8.68e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.12e-06	8.58e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.11e-06	8.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.11e-06	8.57e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTR—hematologic cancer	4.08e-06	8.5e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.08e-06	8.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—hematologic cancer	4.07e-06	8.48e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOR1—hematologic cancer	4.02e-06	8.36e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—hematologic cancer	4.02e-06	8.36e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ENO2—hematologic cancer	4e-06	8.34e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCB1—hematologic cancer	3.9e-06	8.12e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.88e-06	8.09e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SDC1—hematologic cancer	3.8e-06	7.91e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—hematologic cancer	3.78e-06	7.88e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOR1—hematologic cancer	3.78e-06	7.88e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—hematologic cancer	3.64e-06	7.57e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.59e-06	7.48e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—hematologic cancer	3.55e-06	7.39e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—hematologic cancer	3.42e-06	7.13e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—hematologic cancer	3.34e-06	6.96e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CD44—hematologic cancer	3.23e-06	6.72e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NQO1—hematologic cancer	3.23e-06	6.72e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.2e-06	6.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CREBBP—hematologic cancer	3.17e-06	6.61e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.05e-06	6.36e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYCS—hematologic cancer	3.05e-06	6.36e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.03e-06	6.32e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CD—hematologic cancer	3.01e-06	6.27e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.98e-06	6.21e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—hematologic cancer	2.97e-06	6.19e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3R1—hematologic cancer	2.84e-06	5.92e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.83e-06	5.9e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.81e-06	5.85e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CREBBP—hematologic cancer	2.76e-06	5.76e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.69e-06	5.61e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.69e-06	5.59e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—hematologic cancer	2.65e-06	5.52e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CB—hematologic cancer	2.62e-06	5.46e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.62e-06	5.46e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.6e-06	5.43e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—hematologic cancer	2.59e-06	5.39e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.55e-06	5.31e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3R1—hematologic cancer	2.54e-06	5.28e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.47e-06	5.15e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.47e-06	5.15e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.47e-06	5.15e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.47e-06	5.14e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—hematologic cancer	2.44e-06	5.08e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.34e-06	4.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.33e-06	4.86e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.28e-06	4.76e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—hematologic cancer	2.27e-06	4.72e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.19e-06	4.55e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EP300—hematologic cancer	2.16e-06	4.5e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.15e-06	4.48e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—hematologic cancer	2.02e-06	4.21e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—hematologic cancer	1.97e-06	4.11e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EP300—hematologic cancer	1.93e-06	4.02e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EP300—hematologic cancer	1.88e-06	3.92e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—hematologic cancer	1.86e-06	3.87e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.84e-06	3.83e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EP300—hematologic cancer	1.77e-06	3.69e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.7e-06	3.55e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.61e-06	3.36e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—hematologic cancer	1.6e-06	3.33e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—hematologic cancer	1.59e-06	3.32e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.52e-06	3.18e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.43e-06	2.97e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.41e-06	2.93e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.39e-06	2.9e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.31e-06	2.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—hematologic cancer	1.31e-06	2.72e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—hematologic cancer	1.22e-06	2.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—hematologic cancer	1.17e-06	2.43e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EP300—hematologic cancer	1.16e-06	2.42e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—hematologic cancer	1.14e-06	2.37e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—hematologic cancer	1.07e-06	2.23e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—hematologic cancer	8.58e-07	1.79e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—hematologic cancer	7.01e-07	1.46e-05	CbGpPWpGaD
